Vaccinex has developed anti-CXCL13 monoclonal antibodies to treat autoimmune diseases, inflammatory diseases, and cancers. The patent covers a method for treating diseases by administering antibodies that specifically bind to CXCL13. Specifically, the method targets diseases like multiple sclerosis, lupus, arthritis, and those associated with Helicobacter bacterial infection. GlobalData’s report on Vaccinex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vaccinex, Personalized cancer vaccines was a key innovation area identified from patents. Vaccinex's grant share as of May 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of autoimmune and inflammatory diseases using anti-cxcl13 antibodies
A recently granted patent (Publication Number: US11981730B2) discloses a method for treating autoimmune and inflammatory diseases by administering an isolated antibody or antigen-binding fragment that specifically binds to CXCL13 in mammals. The antibody comprises specific regions in the heavy and light chain variable regions and is effective in treating diseases such as multiple sclerosis (MS), Systemic Lupus Erythematosis (SLE), arthritis, and inflammatory diseases associated with Helicobacter bacterial infections.
Moreover, the patent also covers a method for treating cancer, including leukemia, lymphoma, and various solid tumors, by administering the same antibody targeting CXCL13. Additionally, the method extends to inhibiting gastric lymphoid follicles, treating gastric or duodenal ulcers in mammals infected with Helicobacter bacteria, with a specific focus on diseases like MALT lymphoma, gastric cancer, and gastritis. The patent emphasizes the potential therapeutic applications of the disclosed antibody in humans for various autoimmune diseases, inflammatory conditions, and cancer types, showcasing a promising avenue for future medical interventions.
To know more about GlobalData’s detailed insights on Vaccinex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
